PTGX
Protagonist Therapeutics Inc

3,285
Loading...
Loading...
News
all
press releases
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Zacks·2mo ago
News Placeholder
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Zacks·3mo ago
News Placeholder
Citi initiates coverage on biotech amid improving sentiment in sector
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.
investing.com·3mo ago
News Placeholder
Protagonist Therapeutics Set to Join S&P SmallCap 600
Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK, June 27, 2024 NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist...
PR Newswire·1y ago
News Placeholder
Dinesh V. Ph D. Patel Sells 25,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh V. Ph D. Patel sold 25,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average...
Zolmax·1y ago
News Placeholder
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
Related Stocks: PTGX...
GuruFocus·1y ago
News Placeholder
Protagonist Therapeutics (PTGX, $28.26) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024
This indicator may be signaling that PTGX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
Protagonist Therapeutics (PTGX, $28.93) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024
This indicator may be signaling PTGX's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks·1y ago
News Placeholder
Protagonist Therapeutics (PTGX, $28.33) price may climb as it broke lower Bollinger Band on Mar 14, 2024
This price move could be a signal that PTGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks·1y ago

Latest PTGX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.